Current status and progress of the treatment of acute promyelocytic leukemia
10.3760/cma.j.issn.1009-9921.2019.09.008
- VernacularTitle: 急性早幼粒细胞白血病治疗的现状和进展
- Author:
Fujia LIU
1
;
Yang SHEN
Author Information
1. Department of Hematology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
- Publication Type:Journal Article
- Keywords:
Leukemia, promyelocytic, acute;
Retinoic acid;
Arsenical;
Molecular mechanisms of pharmacological action;
Drug-resistance mechanisms
- From:
Journal of Leukemia & Lymphoma
2019;28(9):546-549
- CountryChina
- Language:Chinese
-
Abstract:
Acute promyelocytic leukemia (APL) is a special type of acute leukemia. The cure rate of APL has been significantly improved in the past decades due to the use of anthracyclines, all-trans retinoic acid and arsenic. Modern stratified treatment of APL further enhances the therapeutic efficacy and reduces the treatment-related toxicity. This article reviews the history of all-trans retinoic acid and arsenic into clinical application, and the characteristics of disease, treatment status of all-trans retinoic acid and arsenic, treatment mechanism and drug resistance mechanism in APL are introduced.
